A prebiotic is a substrate that is selectively utilized by host microorganisms conferring a health benefit. This definition requires that prebiotics (1) reach microorganisms intact, (2) that selected microorganisms use them as substrate and (3) that they mediate health benefits via the microorganisms. Human milk oligosaccharides (HMO) reach the gut intact. They are selective substrates for Lactobacilli and Bifidobacteria strains. Whether HMO reveal health benefits via the microorganisms is actively under investigation.
Since 2017, prebiotics (→) are defined by the the International Scientific Association for Probiotics and Prebiotics (ISAPP) as “a substrate that is selectively utilized by host microorganisms conferring a health benefit.” This statement keeps a microbiota-mediated health benefit but does not restrict a prebiotic component to be a food or carbohydrate nor are the effects limited to the gastro-intestinal tract (Gibson et al. 2017). This definition still requires that a prebiotic substance
HMO are resistant to digestive enzymes which makes them predominantly non-digestible fibres and are unaffected by intestinal pH (Engfer et al. 2000; Gnoth et al. 2000); only 1-2% of HMO are absorbed in the small intestine. Consequently, many HMO are reaching the colon intact (Obermeier et al. 1999) where individual isoforms are candidate prebiotics by serving as nutrient source for specific colonic microbiota species (Gibson et al. 2017).
The HMO fraction as total has been associated with the establishment of a favourable intestinal microbiome (Kunz. 2012). When comparing the gut microbiome of breastfed and non-breastfed infants, different bacterial composition was identified (Harmsen et al. 2000). The predominance of Bifidobacteria species in breastfed infants was attributed to HMO presence (Kunz. 2012). When adding the two industrially generated HMO isoforms 2'‑fucosyllactose (2'-FL) and lacto-N-neo-tetraose (LNnT) as mixture to infant formula, a shift of the stool microbiota composition was detected towards a similar composition to that of breastfed infants (Steenhout et al. 2016). Similarly, in vitro studies on cell lines are supporting a HMO-mediated growth advantage for beneficial over pathogenic bacteria (Sela and Mills. 2010). Individual HMO types, including 2'‑fucosyllactose, 3'‑fucosyllactose (3'-FL), lacto‑difucotetraose, 3'‑sialyllactose (3'-SL), and 6'‑sialyllactose (6'-SL), promote the growth of Bifidobacteria strains (B. infantis, B. bifidus, B. breve, B. longum), Bacteroides genera, and specific Lactobacillus species (Lactobacillus delbrueckii) (Lewis et al. 2015; Yu et al. 2012). This may be due to the specialised ability of B. breve, B. infantis, and most B. longum species of using fucosylated HMO as growth substrate that these pathogens lack (Sakanaka et al. 2019). In contrast, many pathogens cannot use these HMO isoforms as growth substrate, including Escherichia coli, Clostridium perfringens, Streptococcus agaltictiae, Enterobacter, Acinetobacter baumannii (Ackerman et al. 2018; Underwood et al. 2015; Yu et al. 2013) or Streptococcus aureus, the latter being one of the most frequent causes for bacterial infections in infants (Lin et al. 2017).
Besides directly affecting microbiota growth by serving as substrate of particular species, HMO are indirectly promoting bacterial growth via cross-feeding (Smith et al. 2019). When bacterial strains ferment HMO and other prebiotic substrates in the intestinal lumen the left-overs and bacterial metabolites serve other bacterial strains as growth substrate (Sela and Mills. 2010). This supports the development of a healthy and diverse microbiota ecosystem.
Demonstrating the third set of requirements for a prebiotic classification of HMO – that is the demonstration of health benefits mediated via colonic microorganisms – has been difficult. This is because – until about the year 2000 – HMO could only be extracted from mother's milk and tested small-scale in laboratory settings. Since then, technological advancements have been making individual HMO isoforms available for large scale clinical studies or commercial productions (→; Bode et al. 2016) and data from clinical safety and/or efficacy studies have been slowly accumulating (Reverri et al. 2018).
Health benefits associated with HMO include
Bode L, Contractor N, Barile D, Pohl N, Prudden AR, Boons G-J, Jin Y-S, Jennewein S. Overcoming the limited availability of human milk oligosaccharides: challenges and opportunities for research and application. Nutrition reviews 2016; 74(10):635–44. at: www.ncbi.nlm.nih.gov/pubmed/27634978
Engfer MB, Stahl B, Finke B, Sawatzki G, Daniel H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. The American journal of clinical nutrition 2000; 71(6):1589–96. at: www.ncbi.nlm.nih.gov/pubmed/10837303
Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature reviews. Gastroenterology & hepatology 2017; 14(8):491–502. at: https://pubmed.ncbi.nlm.nih.gov/28611480
Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2'-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. The Journal of nutrition 2016; 146(12):2559–66. at: https://pubmed.ncbi.nlm.nih.gov/27798337
Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, Welling GW. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. Journal of pediatric gastroenterology and nutrition 2000; 30(1):61–7. at: https://journals.lww.com/jpgn/Fulltext/2000/01000/Analysis_of_Intestinal_Flora_Development_in.19.aspx
La Fata G, Rastall RA, Lacroix C, Harmsen HJM, Mohajeri MH, Weber P, Steinert RE. Recent Development of Prebiotic Research-Statement from an Expert Workshop. Nutrients 2017; 9(12). at: https://pubmed.ncbi.nlm.nih.gov/29261110
Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, van Tassell ML, Miller MJ, Jin Y-S, German JB, Lebrilla CB, Mills DA. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 2015; 3. at: www.ncbi.nlm.nih.gov/pubmed/25922665
Lin AE, Autran CA, Szyszka A, Escajadillo T, Huang M, Godula K, Prudden AR, Boons G-J, Lewis AL, Doran KS, Nizet V, Bode L. Human milk oligosaccharides inhibit growth of group B Streptococcus. The Journal of biological chemistry 2017; 292(27):11243–9. at: www.ncbi.nlm.nih.gov/pubmed/28416607
Obermeier S, Rudloff S, Pohlentz G, Lentze MJ, Kunz C. Secretion of 13C-labelled oligosaccharides into human milk and infant's urine after an oral 13Cgalactose load. Isotopes in environmental and health studies 1999; 35(1-2):119–25. at: www.ncbi.nlm.nih.gov/pubmed/1092537
Reverri EJ, Devitt AA, Kajzer JA, Baggs GE, Borschel MW. Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2'-Fucosyllactose. Nutrients 2018; 10(10). at: www.ncbi.nlm.nih.gov/pubmed/30241407
Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, Los Reyes-Gavilán CG de, Salazar N. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. Frontiers in microbiology 2016; 7:185. at: https://pubmed.ncbi.nlm.nih.gov/26925050
Sakanaka M, Hansen ME, Gotoh A, Katoh T, Yoshida K, Odamaki T, Yachi H, Sugiyama Y, Kurihara S, Hirose J, Urashima T, Xiao J-z, Kitaoka M, Fukiya S, Yokota A, Lo Leggio L, Abou Hachem M, Katayama T. Evolutionary adaptation in fucosyllactose uptake systems supports bifidobacteria-infant symbiosis. Science Advances 2019; 5(8). at: https://pubmed.ncbi.nlm.nih.gov/31489370
Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends in microbiology 2010; 18(7):298–307. at: https://pubmed.ncbi.nlm.nih.gov/20409714
Smith NW, Shorten PR, Altermann E, Roy NC, McNabb WC. The Classification and Evolution of Bacterial Cross-Feeding. Front. Ecol. Evol. 2019; 7:153. at: https://www.frontiersin.org/articles/10.3389/fevo.2019.00153/pdf
Steenhout P, Sperisen P, Martin F-P, Sprenger N, Wernimont S, Pecquet S, Berger B. Term infant formula supplemented with human milk oligosaccharides (2'-fucosyllactose and Lacto-N-neotetraose) shifts stool microbiota and metabolic signatures closer to that of breastfed infants.: This abstract is from the Experimental Biology 2016 Meeting. There is no full text article associated with this abstract published in The FASEB Journal. FASEB J. 2016; 2016(30):275–7. at: https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.30.1_supplement.275.7
Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatric research 2015; 77(1-2):229–35. at: www.ncbi.nlm.nih.gov/pubmed/25303277
Yu Z-T, Chen C, Kling DE, Liu B, McCoy JM, Merighi M, Heidtman M, Newburg DS. The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology 2012; 23(2):169–77. at: www.ncbi.nlm.nih.gov/pubmed/23028202
Yu Z-T, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology 2013; 23(11):1281–92. at: www.ncbi.nlm.nih.gov/pubmed/24013960back